Palapala Hoʻo Hou > Nā lāʻau lapaʻau

Oral hypoglycemic ahente, kahi phenylalanine derivative. I nā lāʻau a me nā mea laila ʻokoʻa ʻole ia i nā ʻokoʻa ʻē aʻe o nā lawena hypoglycemic. Hoʻopili i ka mea huna mua o ka insulin, kahi e hoʻoneʻe ai i ka hoʻemi ʻana o ka hoʻōla o postprandial i loko o ke koko a me ka pae o ka hemoglobin glycated (HbA1c).

Ma lalo o ka mana o ka nateglinide i lawe ʻia ma mua o ka papaʻaina, hoʻihoʻi ʻia ka mua (a mua paha) o ka loaʻa ʻana o ka inikini insulin. ʻO ka hana o kēia hanana ka wikiwiki a me ka hoʻihoʻi o ka nateglinide me nā K + ATP hilinaʻi-kūkaʻi o ka pancreatic β-cell. ʻO ke koho o nateglinide e pili ana i nā kahawai o K + ATP e hilinaʻi nei i nā pancreatic β-cells he 300 mau kiʻekiʻe ma mua o ka mea e pili ana i nā kahawai o ka puʻuwai a me nā kīʻaha koko.

ʻO Nateglinide, ʻaʻole like me nā mea maʻi waha hypoglycemic waha, e hoʻoiho i ka mea huna o ka insulin i loko o nā 15 mau minuke mua ma hope o ka ʻai ʻana, ma muli o kēlā mau ʻano peʻemaka postprandial ("peaks") i ka hoʻōho o ka glucose koko i waho. I nā hola he 3-4 e hiki mai ana, hoʻi ka pae i ka insulin i kona mau waiwai mua, no laila, hiki ke pale aku i ka hoʻomohala ʻana o ka hyperinsulinemia postprandial, hiki iā ia ke hoʻomau i ka hypoglycemia.

ʻO ka huna ʻia o ka insulin e ka pancreatic β-cells i hoʻokumu ʻia e nateglinide e hilinaʻi nei i ka pae o ka glucose i loko o ke koko, ʻo ia hoʻi, ma ka hoʻoli ka ʻana o nā glucose. ʻO ka hōʻuluʻulu ʻana, nā manawa a i ʻole nā hoʻopili ʻana o ka hopena glucose e alakaʻi i kahi hoʻonui hoʻonui ʻia i ka huna ʻana i ka insulin.

Lawe i loko. Me ka monotherapy - 120-180 mg 3 manawa / lā. Ke lawe nei i kahi hoʻohui hui - 60-120 mg 3 manawa / lā.

Nā hopena hopena

Mahalo: nā hōʻailona presumably e hōʻike ana i ka hoʻomōhala o ka hypoglycemia - hoʻonui i ka honi, nā pā, ka ʻalā, ke hoʻonui ʻana i ka makemake, palpitations, nausea, nāwaliwali, malaise (ʻo ka maʻamau kēia mau ʻōmaʻomaʻo he mau haʻahaʻa a maʻalahi hoʻi i ka lawe ʻana i ka mauʻu).

Kākela: nui ka hana o ka hoʻōla o ka hepatic i loko o ke koko (ma ka maʻamau o ka maʻalahi a me ka palaualelo), ka ʻū, ka puhaluhi, ka urticaria.

ʻO ka maʻi diabetes mellitus type 2 (non-insulin-dependant) - me ka hana ʻole o ka papa ʻaina a me ka hana kino (ma ke ʻano ʻano monotherapy a i hui pū ʻia me nā lāʻau lapaʻaka hypoglycemic).

Nā ʻōlelo kikoʻī

ʻO ka hopena o ka hoʻomohala ʻana i ka hypoglycemia aʻo ka lawe ʻana i ka nateglinide (e like me nā lāʻau lapaʻaka hypoglycemic) e kiʻekiʻe loa i nā mea maʻi me ka kaumaha o ke kino, ma ke alo o ka adrenal a i ʻole ka hoʻopihapiha pituitary. Hiki ke hoʻoneʻe ʻia ka hoʻoliʻiliʻi ʻana o ka hoʻoliʻiliʻi o ka koko e ka ʻai ʻana i ka wai ʻona, hoʻonui ʻia ke ʻano kino, a me ka hoʻohana ʻana o ka lāʻau hypoglycemic kekahi.

Hiki i ka hoʻohana pinepine ʻana i nā beta-blockers ke uhi i nā hōʻike o ka hypoglycemia.

Hoʻokomo i ka hiki ke lawe i nā kaʻa a kāohi i nā mīkini

ʻO nā mea maʻi e hana pū ana me nā mīkini a me ke kaʻa kaʻa e pono e mālama i ka mālama kūikawā e pale ai i ka hypoglycemia.

Nā hōʻailona no ka hoʻohana ʻana

Hōʻike ʻia ka Nateglinide e monotherapy no ka hoʻohaʻahaʻa i ka nui o ke kaila koko i loko o nā mea maʻi me ka diabetes mellitus type 2 (non-insulin-depend a diabetes mellitus) i nele ka ʻai a hoʻomaʻamaʻa e kāohi i kā lākou glycemia a ʻaʻole i mālama ʻia no ka manawa lōʻihi me nā lawena hypoglycemic ʻē aʻe.

Ua hōʻike ʻia nō ʻo Nateglinide no ka hoʻomohala ʻana i ka hui me ka metformin i nā mea maʻi me ka ʻike ʻole o ka glycemia e kū aʻe ana i ka mea o ke ʻano o ka metformin (ʻaʻole i aʻo ʻia e kū i ke metformin me ka nateglinide).

Lapaʻau lāʻau

Oral hypoglycemic ahente, kahi phenylalanine derivative. I nā lāʻau a me nā mea laila ʻokoʻa ʻole ia i nā ʻokoʻa ʻē aʻe o nā kumuwaiwai hypoglycemic. Hoʻopili i ka mea huna mua o ka insulin, kahi e hoʻoneʻe ai i ka hoʻemi ʻana o ka hoʻōla o postprandial i loko o ke koko a me ka pae o ka hemoglobin glycated (HbA1c).

Lapaʻau lāʻau

Hoʻopau Ma hope o ka helu ʻana ma mua o ka ʻai, ua hopu koke ʻia ka nateglinide, ua loaʻa ka Cmax i ka plasma i ka awelika ma loko o ka hola 1. I ke kuhikuhi ʻana ʻo nateglinide i nā mea maʻi me ka maʻi diabetes mellitus type 2 a i nā 60 a 240 mg 3 mau manawa i ka lā no 1 hebedoma, he hilinaʻi kūlike i nā AUC a me ka linear. a me Cmax mai ka pōʻai. ʻAʻole i hilinaʻi ʻo Tmax i kēia mau maʻi. ʻO ka bioavailability piha kūpono e pili ana i ka 73%. I ka manawa a lawe ʻia a ʻai ʻole i ka ʻai, ʻaʻole mau i loli ʻole ka nateglinide (AUC), akā i nānā ʻia ka lohi ʻana ma ke kō ʻana o ka absorption, ʻike ʻia e ka emi ʻana o Cmax a me kahi hoʻonui o Tmax. Ke lawe nei i ka nateglinide ma kahi honu ʻōpū, ʻike ʻia nā ʻike o ka plasma ma ke ʻano he nui. ʻAʻole mālama ʻia kēia hopena i ka wā e lawe ai i ka nateglinide ma mua o ka papaʻaina.

Kahele. Wahi a nā hōʻike, me ka / i ka hoʻomaka ʻana o ka nateglinide, ka nui o ke kahe ʻana ma kahi kūlana e hoʻohālikelike ai i kahi kanaka olakino he 10 lita. Hoʻopaʻa ka Nateglinide i ka 98% me nā protein serum, ʻoi aku me ka albumin, i kahi haʻahaʻa loa - me ka glycoprotein α1-acid. ʻAʻole ka mea i hilinaʻi i ka protein protein i ka neʻe ʻana o ka mea i loko o ka neʻe ʻana ma ka 0.1 a 10 μg / ml.

Hāpai. Ma mua o ka hoʻopuka ʻana, ʻānō ʻia ka nateglinide me ke komo ʻana o kahi ʻōnaehana oxidase multifunctional. ʻO ke ala nui nui o ka metabola ʻo ka hydroxylation, e hahai ana i ka glucuronide. ʻO nā metabolites koʻikoʻi ka mea nāwaliwali loa i ka hopena hypoglycemic ma mua o nateglinide. ʻO ka metabolite liʻiliʻi - isoprene - ua like ia me ka ikaika me nā mea kumu mua o ka nateglinide. Wahi a nā haʻawina vitro, ʻike nui ʻia ka nateglinide me ke komo ʻana o ka cytochrome P450: isoenzyme CYP2C9 (70%) a me CYP3A4 (30%).

Leʻaleʻa. ʻO Nateglinide a me kāna mau metabolites wikiwiki a hoʻopiʻi loa ʻia ma hope o ka lawelawe waha. Ma loko o 6 mau hola, ʻike ʻia ka 75% o ka nui o ka nateglinide i kāhea ʻia me ka carbon 14C i ʻike ʻia i loko o ka urine. ʻO 83% o 14C-nateglinide ua hoʻopiʻi ʻia e nā keiki, 10% - ma o ka huina. Ma kahi o 16% o nateglinide i hoʻopaʻa ʻia me 14C i hoʻoholo ʻia e hoʻololi ʻole ʻia ma ka urine. I nā ʻikepili āpau i nā limahana olakino a me nā mea maʻi me ka diabetes mellitus type 2, ke piʻi wikiwiki nei ka ʻike ʻana o ka nateglinide i ka plasma, ʻo 1.5 ka manawa awelika he 1.5 mau hola. E like me kēlā me ka hapalua pōkole, ʻaʻole kūlike ka kulu o nateglinide me nā dosis he nui a hiki i 240 mg 3 mau lā i kahi lā no 7 lā.

ʻO ka pilina me nā lāʻau lapaʻau ʻē aʻe

I loko o nā noiʻi vitro metabolism hōʻike i hōʻike ʻia ka nateglinide i hoʻohālikelike nui me ka komo ʻana o ka cytochrome P450: isoenzymes CYP2C9 (70%) a, i kahi liʻiliʻi, CYP3A4 (30%). ʻO Nateglinide kahi mea hoʻomehana nui o ka isoenzyme CYP2C9 i vivo, e like me ka hōʻike ʻana iā ia i kona hiki ke hoʻēmi i ka vitro metabolism o tolbutamide. ʻO ka hopena metabolic o ka huina CYP3A4 ʻaʻole i ʻike ʻia i nā hoʻokolohua vitro.

Hoʻolālā. Ma kahi helu manuahi, noiʻi ʻia he kano pākahi, ʻaila nā mea maʻi me ka maʻi diabetes type 2 i kuhikuhi ʻia i ka nateglinide 120 mg 3 mau lā i kēlā me kēia lā ma mua o ka lā i ka lā 1 me ka 10 mg o glyburide. ʻAʻohe mea loli i ʻike ʻia i loko o nā pharmacokinetics o nā mea ʻelua.

Metformin. I ka hoʻohālikelike ʻia ʻana i nā mea maʻi me ka diabetes type 2 mellitus nateglinide (120 mg) 3 mau manawa i ka lā ma mua o ka papa i hui pū ʻia me metformin 500 mg 3 mau manawa i kahi lā, ʻaʻohe mau maʻi i ʻike ʻia i loko o ka pharmacokinetics o nā mea ʻelua.

Digoxin. I ka hoʻoneʻe ʻia ʻana o 120 mg o nateglinide i nā mea hana olakino olakino 3 mau manawa i ka lā ma mua o ka papaʻa, me ka hui pū ʻana me hoʻokahi dosis o 1 mg o digoxin, ʻaʻohe ʻano loli o ka lapaʻau i nā pharmacokinetics o nā mea ʻelua.

Warfarin. I ka manawa i kuhikuhi ʻia ai nā mea hana olakino 120 mg nateglinide mau manawa 3 i ka lā ma mua o ka pāʻina no ka 4 lā i hui pū ʻia me hoʻokahi dosis o 30 mg o warfarin i ka lā lua, ʻaʻohe mea i loli i ka pharmacokinetics o nā mea ʻelua, ʻaʻole i loli pū ʻo PV.

Diclofenac. I ke kakahiaka a i ke ahiahi, 120 mg o nateglinide i hui pū ʻia me kahi hoʻokahi like o 75 mg o diclofenac ʻaʻole i alakaʻi i nā loli nui i loko o ka pharmacokinetics o nā mea ʻelua i loko o nā mea kōkua ola maikaʻi.

ʻO ka hapa nui o nateglinide (98%) ikaika paʻa i nā protein plasma, nui i ka albumin. I nā haʻawina vitro o ka hoʻomaha me nā mea me ke koʻo o ke kūkaʻa nui, e like me ka furosemide, propranolol, captopril, nicardipine, pravastatin, glyburide, warfarin, phenytoin, acetylsalicylic acid, tolbutamide a metformin, ʻaʻole i hōʻike i ka hopena o ka huina o ka nateglinide i nā protein plasma. ʻAʻole i hoʻopilikia ʻo Nateglinide i ka palena o ka protein protein e pili ana i ka propranolol, glyburide, nicardipine, phenytoin, acetylsalicylic acid a me tolbutamide i vitro. Eia nō naʻe, ma nā kūlana lapaʻau e hiki ke hōʻiliʻili nā liʻiliʻi liʻiliʻi.

ʻO kekahi mau lāʻau lapaʻau, e komo ai Nā NSAID, salicylates, inhibitor MAO a me nā beta-blocker koho ʻaʻole hiki ke hoʻoikaika i ka hopena hypoglycemic o ka nateglinide a me nā mea hana hypoglycemic āpau.

ʻO kekahi mau lāʻau, e pili ana i ka diuret thiazide, corticosteroids, kaomi analog o ka thyroid, sympathomimetics, hiki ke hōʻemi i ka hopena hypoglycemic o nateglinide a me nā mea hana waha hypoglycemic waha. Ke kuhikuhi ʻia nei nā lāʻau lapaʻau a kāpae ʻia paha i ka mea maʻi e loaʻa ana i nateglinide, pono e nānā i ke pae o ka glycemia.

Hoʻohui pili i nā meaʻai. ʻAʻole hilinaʻi ka pharmacokinetics o nateglinide i ka hoʻopili ʻana o ka meaʻai (protein, momona, a ʻona wale nō hoʻi). Eia nō naʻe, ua hoʻemi nui ʻia Cmax i ka wā e lawe ai i ka nateglinide mau minuke 10 ma mua o ka lawe ʻana i ka meaʻai wai. ʻAʻohe hopena o Nateglinide i kahi ʻōpū hoka ʻole i nā poʻe olakino, e like me ka hōʻike ʻana i ka hōʻike acetaminophen.

Hoʻomaʻamaʻa no ka hoʻohana

Hypoglycemia. Hiki i nā lawelawe āpau hypoglycemic āpau ke kumu i ka hypoglycemia. Ma muli o ka pinepine o ka hypoglycemia ma muli o ka nui o ka maʻi o ka maʻi maʻi, ka kaohi o ka glycemia a me nā ʻano ʻē aʻe o ka mea maʻi. ʻO nā maʻi a me nā poʻe senile, nā mea maʻi me nā mea ʻai maikaʻi, nā mea maʻi me ka nele o adrenal a i ʻole pituitary e hiki ke maʻalahi i ka hopena hypoglycemic o kēia hopena. Hiki i ka pilikia o ka hypoglycemia ke hoʻonui me ka hoʻoikaika kino kino, inu ʻona, me ka ʻole o ka waiwai o ke kaloli (lōʻihi a i ʻole ulia paha), a i hui pū ʻia me nā mea maʻi waha hypoglycemic a pau. A paʻakikī paha e ʻike i ka hypoglycemia i nā maʻi me ka autonomic (visceral) neuropathy a / a i ʻole ke lawe ʻana i nā beta-blockers. No ka hōʻemi i ka hopena o ka hypoglycemia, ua kuhikuhi ʻia ka nateglinide ma mua o ka ʻai, ʻo ka mea maʻi e kuke ana i nā meaʻai e pono ai kekahi i nā nateglinide e hiki mai ana.

Pilikia ka pehu. Pono e hoʻohana ʻia ʻo Nateglinide me ka makaʻala i nā mea maʻi me ka maʻi maʻi palupalu i hōʻemi a maʻi ʻole paha, ʻoiai ʻo ka hoʻohana ʻia ʻana ma ia mau mea like ʻole i hoʻokolokolo ʻia.

Nalo o ka mālama glycemic. Hiki i ka nalowale ke hiki aku o ka mālama glycemic me ke keokeo, nā maʻi, ka trauma, a me nā mea hana. I kēia mau hihia, ma kahi o nateglinide, pono e pono ka therapy insulin. Ka lawa a i ʻole ka hōʻemi ʻana i ka hopena o ka nateglinide e hiki mai ma hope o kekahi manawa.

Nā hōʻike hōʻike Laboratory. Pono ka pane ʻana i ka mālama ʻana i ka loiloi i kēlā me kēia hoʻohuihui glucose me ka pae HbA1c.

ʻO ka wehewehe ʻana i ka lāʻau lapaʻau

Nateglinide - He waha hypoglycemic aihue, kahi phenylalanine derivative. I nā lāʻau a me nā mea laila ʻokoʻa ʻole ia i nā ʻokoʻa ʻē aʻe o nā kumuwaiwai hypoglycemic. Hoʻihoʻi i ka mea huna o ka wina o ka insulin, kahi e hoʻoneʻe ai i ka hoʻemi ʻana o ka hoʻokaʻina o ka glucose i loko o ke koko a me ka pae o ka hemoglobin glycated (HbA 1c).

Kahi papa inoa o nā kūmole

E hoʻokuʻu i ke ʻano (ma o ke kaulana)	Kūʻai, rub.
Nateglinide
ʻAmbekoe *
Starlix

Ua hōʻike aku kahi mea kipa i kahi lā pau

Pehea ka lōʻihi e lawe ai iā Nateglinide e manaʻo i ka holomua o ke kūlana o ka mea maʻi?
ʻO ka poʻe ʻikepili o ka noiʻi i nā hapa he nui ma hope o 1 lā i manaʻo ai kahi holomua. Akā ʻaʻole paha e kūpono kēia i ka manawa āu e hoʻomaikaʻi ai. E nīnau aku i kāu kauka no ka lōʻihi o kou makemake e lawe i kēia lāʻau lapaʻau. Hōʻike ka papa ma lalo nei i nā hopena o ka noiʻi ma ka hoʻomaka ʻana o kahi hana kūpono.

Nā lālā

1 lā

Ua hōʻike aku ʻekolu kipa i nā makahiki ahonui

Nā lālā	%
46-60 makahiki	1

33.3%

30-45 mau makahiki

33.3%

> 60 mau makahiki

Nā manaʻo hoihoi

Pehea e koho ai i ka analog kūpono
I loko o ka pharmacology, hoʻokaʻawale pinepine nā lāʻau i nā ʻ synlelo a me nā kikowaena. Hoʻokomo ʻia i ke ʻano o nā like o nā ʻano like ʻole i ke ʻano he hopena therapeutic ma ke kino. Ke hoʻohālikelike nei nā analogs i nā lāʻau lapaʻau e pili ana i nā ʻano like like ʻole, akā no ka mālama ʻana i nā maʻi like.

ʻO nā ʻokoʻa ma waena o nā maʻi a me nā maʻi bacterial
Hoʻopilikia ʻia nā maʻi maʻi e nā maʻi, nā maʻi, nā fungi a me ka protozoa. ʻO ke ʻano o nā maʻi i hoʻomake ʻia e nā maʻi a me nā maʻi like ʻole. Eia nō naʻe, ka hoʻokaʻawale i ke kumu o ka maʻi i ke koho e kūpono i ke ʻano kūpono e kōkua ai i ka hoʻokē ʻana i ka malaise a ʻaʻole ʻoe e hōʻino i ke keiki.

ʻO nā maʻi āpau ke kumu o ke anuanu pinepine
ʻIke kekahi poʻe i kahi kūlana i kahi pinepine ke keiki a a lōʻihi no ka manawa anuanu. Lawe nā mākua iā ia i nā kauka, lawe i nā hoʻokolohua, lawe i nā lāʻau lapaʻau, a ma muli o ke ʻano, ua hoʻopaʻa inoa ʻia ke keiki me ke keiki e like me ka maʻi nui. ʻAʻole i ʻike ʻia nā kumu maoli o nā maʻi ʻeha pinepine.

Urology: hana maʻi urethritis chlamydial
Loaʻa pinepine ʻia Chlamydial urethritis ma ka hana o kahi urologist. Hoʻokumu ʻia e ka intracellular parasite Chlamidia trachomatis, aia nō nā waiwai o nā huakini a me nā maʻi like, ua makemake pinepine i ka antibiotic therapy regimens no ka maʻi antibacterial. Hiki iā ia ke hana i ka mumū ʻole o ka maʻi o ka urethra i nā kāne a me nā wahine.

Nā hōʻailona a me nā contraindications no ka hoʻohana ʻana, overdose

Hoʻohana ʻia ka Nateglenide inā hoʻohana ka mea maʻi i ka diabetes mellitus non-insulin-like me kaʻole o nā hoʻololi maikaʻi i ka wā e hoʻohana ai i ka papa hana meaʻai a me ka hoʻoikaika kino olakino.

Hiki ke hoʻohana ʻia ka lāʻau lapaʻau ma ka wā o ka monotherapy a ma ke ʻano he hana i loko o ka hoʻomehana paʻakikī i ka mālama ʻana i ka maʻi type 2.

I ka manawa pinepine, hoʻohana ʻia ka lāʻau lapaʻau me ka hui pū me ka Metformin.

Ke hoʻohana nei i ka lāʻau lapaʻau, loaʻa nā helu contraindications i kona hoʻohana. ʻO ka mea nui i waena o nā contraindications i ka hoʻohana ʻana o Nateglinide ka mea i laila:

ka loaʻa ʻana o ka maʻi maʻi type 1 i ka mea maʻi,
ka heleʻana o kahi mea maʻi me nā maʻi mellitus maʻi mellitus o ka hoʻomohala ʻana i ka ketoacidosis maʻi,
ka ʻike ʻana i ka maʻi hana koʻikoʻi ma ka pūpū,
ka wā gestation a me ka wā hana umauma,
kona wā ʻōpiopio me ka maʻi maʻi,
ka heleʻana o ka hoʻonui i ka naʻau i nā mea i hoʻokomo ʻia i ka hoʻonohonoho o ka lāʻau.

Hoʻokumu i ka hana o ka hopena o ka lāʻau lapaʻau ma ke kino, hiki ke manaʻo ʻia i ka hopena koʻikoʻi o ka hoʻonāukiuki ʻia o ka paukana i ʻōlelo ʻia i ka mālama ʻana i ka maʻi maʻi kōpili o ka ulu ʻana o ka hypoglycemia i ka mea maʻi, ka mea hiki iā ia ke hōʻike iā ia iho i nā ʻano like ʻole o ka palaleka paʻa i ka nui o ka overdose i ka wā lapaʻau.

Koho ke ʻano o ke ala no ka mālama ʻana i nā maʻi overdose e pili ana i ka pae o ka hōʻike.

ʻOiai e mālama nei i ka ʻike o ka mea maʻi a me ka nīna ʻole o ka hōʻike neurological, ua ʻōlelo ʻia e lawe i ka glucose a i ʻole ka wai gula i loko a hoʻoponopono i ka hoʻopiʻi ʻana i ka meaʻai.

Me ka hoʻomohala ʻana i kahi kūlana koʻikoʻi o ka kūlana hypoglycemic, kahi e ulu ai kahi hōʻea a me nā hoʻokuʻi, ʻike ʻia e hoʻokō i ka kūlohelohe intravenous.

ʻO ke kaʻina he hemodialysis he hana kūpono ʻole, ʻoiai ʻo Nateglitin kahi kiʻekiʻe i hoʻohālikelike ʻia i nā protein plasma koko.

Nā ʻōkuhi no ka hoʻohana ʻana i ka lāʻau lapaʻau

ʻO ka lawe ʻana i ka lāʻau lapaʻau no ka maʻi maʻi ma loko.

I ka hihia o ka monotherapy, kahi maile o 120-180 mg ʻekolu mau manawa i kuhikuhi ʻia i kahi lā.

Inā hoʻohana ʻia ʻo Nateglinide e like me kekahi o nā mea hoʻohui o ka lāʻau paʻakikī, ʻo ke ʻano i ʻōlelo ʻia ma ke ʻano he lapaʻau mai ka 60 a hiki i ka 120 mg ʻekolu mau manawa i ka lā.

Ke hoʻohana nei i ka lāʻau lapaʻau, hiki i ka mea maʻi ke hoʻomohala i kekahi mau hopena ʻaoʻao i ke kino.

Hōʻike nā ʻaoʻao ma ka lawe ʻana i ka lāʻau lapaʻau i ka hana ʻole ʻana o nā ʻenehana a me nā ʻāpana o ke kino o ka mea maʻi.

Hoʻowahāwahā i nā ʻōnaehana o ka palupalu a me nā unuhi naʻau.
Hoʻopilikia i nā hana o ka ʻōnaehana hanu.
Hoʻopau i ka gastrointestinal tract.
ʻO ka hoʻopauʻana o nā kaʻina metabolic.

Eia kekahi, hiki i nā hopena ʻaoʻao ke hopena i ka kūlana maʻamau o ke kino.

Inā nā pilikia i ka hana o ka ʻōnaehana o ka nīnao, ʻike ka mea maʻi i ka maʻi ʻeha.

Hōʻike ʻia ka malfunctions o ka ʻōnaehana hanu e ka ʻike ʻana o nā maʻi i ka hanu ʻana i ka mea maʻi, ka hoʻomohala ʻana i nā hōʻailona o ka bronchitis, a me ka ʻike ʻia o ka ʻōpū.

I ka hanana ʻana o nā hopena ʻeha e hoʻopili ana i ka hana o ke kuapo gastrointestinal, ʻo ka mea maʻi i ke ʻano o ke ʻano o ka maʻi a me ka manaʻo ʻana o ka ʻōpū.

ʻO ka hopena koʻikoʻi o ka maʻi kūlohelohe o ka hoʻomohala ʻana o kahi kūlana hypoglycemic i loko o ke kino o ka mea maʻi, a i nā hihia koʻikoʻi o ka comly glycemic.

ʻO ka hoʻomohala ʻana o kahi kūlana hypoglycemic me ka hoʻohana ʻana o Nateglinide i ka wā lapaʻau ka ʻemi nui loa.

ʻO ke ʻano ʻeha a me ke ʻano maʻi e like me nā hopena mai ka lawe ʻana i ka lāʻau, ʻike pinepine ʻole ʻia.

ʻO kekahi manawa, i ka wā e lawe ai iā Netelinid i kahi maʻi me ka maʻi mellitus, ʻike ʻia ke ʻano o ke ʻeha i ka pōiwi.

Eia kekahi, hoʻomohala paha nā ʻano like ʻole i nā mea maʻi.

Nā hiʻohiʻona o ka lāʻau lapaʻau, mālama a me nā kumukūʻai o ka lāʻau lapaʻau

Pono e mālama i ka lāʻau ma kahi wahiʻeleʻele. ʻO ka mālama mālama o ka lāʻau pono ka i waena o 15 a 30 degere Celsius.

ʻO ʻelua mau makahiki ka noho o ke ola o ka lāʻau. Ma hope o ka pau ʻana o ka manawa mālama, ua pāpā ʻia ka lāʻau lapaʻau e hoʻohana no ka mālama ʻana. Pono nā huahana pau i hoʻopau ʻia.

ʻAʻole pono e loaʻa i ka wahi i waiho ai i nā lāʻau maʻi nā keiki.
I kēia lā, ʻo ka ʻoihana kūʻai lapaʻau e hana i kahi nui o nā lāʻau lapaʻau e loaʻa ai ka hopena like ma ke kino o ka mea maʻi me ka maʻi type 2.

I nā ʻano maʻi maʻamau no ka hopena like ʻole: